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8 Departament de Ciències Cĺıniques, Universitat de Barcelona, Barcelona, Spain
9 Girona Biomedical Research Institute (IDIBGI), Salt, Spain
10ISGlobal, Center for Research in Environmental Epidemiology (CREAL), Spain
11Department of Epidemiology & Cancer Control (S6050), St. Jude Children’s Research Hospital, Memphis, TN, USA
12School of Public Health, University of Alberta, 4-274, Edmonton Clinic Health Academy, Edmonton, AB, Canada
13Bloomberg Faculty of Nursing and Dalla Lana School of Public Health, University of Toronto, Canada
14Health Inequalities Research Group-Employment Conditions Network (GREDS-EMCONET),
Department of Political and Social Sciences, Universitat Pompeu Fabra, Barcelona, Spain
15Johns Hopkins University, Public Policy Center, Barcelona, Spain
16Grupo de Investigación Transdisciplinar sobre Transiciones Socioecológicas (GinTRANS2),
Universidad Autónoma de Madrid, Madrid, Spain
Correspondence should be addressed to Montse Vergara-Duarte; mvergara.bcn.ics@gencat.cat
Received 1 September 2017; Revised 8 February 2018; Accepted 9 May 2018; Published 2 September 2018
Academic Editor: Barthélémy Kuate Defo
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Background. Amenablemortality, or premature deaths that could be preventedwithmedical care, is a proven indicator for assessing
healthcare quality when adapted to a country or region’s specific healthcare context. This concept is currently used to evaluate the
performance of national and international healthcare systems. However, the levels of efficacy and effectiveness determined using
this indicator can vary greatly depending on the causes of death that are included. We introduce a new approach by identifying a
subgroup of causes for which there are available treatments with a high level of efficacy.These causes should be considered sentinel
events to help identify limitations in the effectiveness and quality of health provision.Methods. We conducted an extensive literature
review using a list of amenable causes of death compiled by Spanish researchers. We complemented this approach by assessing the
time trendsof amenablemortality in twohigh-income countries that have a similar quality of healthcare but verydifferent systemsof
provision, namely, Spain and theUnited States.This enabled us to identify different levels of efficacy of medical interventions (high,
medium, and low). We consulted a group of medical experts and combined this information to help make the final classification of
sentinel amenable causes of death. Results. Sentinel amenable mortality includes causes such as surgical conditions, thyroid diseases,
and asthma.The remaining amenable causes of death either have a higher complexity in terms of the disease or needmore effective
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medical interventions or preventative measures to guarantee early detection and adherence to treatment. These included
cardiovascular diseases, diabetes, hypertension, all amenable cancers, and some infectious diseases such as pneumonia, influenza,
and tuberculosis. Conclusions. Sentinel amenable mortality could act as a good sentinel indicator to identify major deficiencies in
healthcare quality and provision and detect inequalities across populations.
1. Introduction
Healthcare systems, and the services they provide, represent
a large economic expenditure for many countries and play
an important role in public health. Healthcare accounts
for around 10% of global GDP, which is mostly spent in
high-income countries [1]. Research shows that a significant
proportion of the global burden of disease could be reduced
through effective medical treatment and prevention [2].
Steady advances in medical technology and knowledge
must be subjected to a complex, continuous process of
evaluation to ensure the efficacy and effectiveness of medical
treatments and procedures [3, 4]. In 1976, Rutstein et al.
introduced the concept of “sentinel health events” as a key
indicator of the quality of healthcare services [5]. This indi-
cator included a heterogeneous set of conditions (i.e., causes
of unnecessary disease, preventable disability, and untimely
death) that should not occur in an adequately functioning
healthcare system. The most effective intervention (treat-
ment, prevention, or both) was identified for each condition
and, for some, restrictions affecting the avoidance of causes
were also shown (e.g., specific circumstances, exposures,
hazards, or age groups).
This seminal proposal was later revisited in the 1990s
by Holland et al. [6], and more recently by Nolte et al.
and Hoffmann et al. From this, the concept of “avoidable
mortality” emerged as a new and useful measure to monitor
the quality of healthcare services and assess the contribution
of healthcare interventions to public health [7, 8]. Within
this context, avoidable causes of death can be classified as
either “preventable” or “amenable.” While preventable causes
include conditions or causes for which premature death
could be avoided through primary preventative interventions
(e.g., national health promotion policies), amenable causes
include conditions for which premature death could be
prevented mainly through secondary or tertiary preventative
interventions (e.g., medical care). This two-group classi-
fication scheme is particularly useful for researching and
evaluating the impact of policies on population health. In
fact, several studies have taken into account both groups
of causes when analysing health inequalities associated with
geographical patterns, social groups, or trends between and
within countries [7–20].
All amenable causes have well-documented evidence
supporting the efficacy of medical interventions in avoiding
premature death. In this respect, efficacy is defined as “the
ability of the science and technology of healthcare to bring
about improvements in health when used under the most
favourable circumstances.” [4] In the last decade, there
have been numerous important medical and technological
advances in the treatment and management of different
causes of death. However, the degree of improvement in
the efficacy of these medical interventions varies markedly
between causes of death, ranging from high levels of efficacy
for surgery on appendicitis and abdominal hernias, for exam-
ple, to relatively low efficacy of interventions for ischemic
heart disease and cerebrovascular diseases [7]. Thus, further
analytical scrutiny of these causes needs to be performed to
properly validate the “amenablemortality” concept [8, 21, 22].
For example, to date no study has systematically classified
the causes of “amenable mortality” according to the level of
efficacy of their respective available medical interventions.
Therefore, in this paper we introduce a new approach
to amenable mortality by identifying “sentinel amenable
mortality”, defined as amenable causes of death for which
highly effective treatments are available. Such causes of
death should be considered sentinel events that can help
identify possible limitations in the effectiveness and quality
of healthcare systems.
2. Methods
We used a list of 27 amenable causes of death that had
been proposal by a group of Spanish experts [23] and later
used in various empirical analyses [10, 24]. From this list,
we excluded any adverse health events because they have a
large variety of causes and are often studied separately as
sentinel events themselves; this results in a final list of 26
amenable causes of death. In Table 1, we summarize the 26
causes of death, age groups, and ICD-9 and ICD-10 codes
(International Classification ofDisease; the Spanish list shows
the correspondence between the two reviews for each cause
of death).
We used two strategies to identify sentinel amenable
causes of death based on the level of efficacy of the available
medical interventions. First, we conducted an extensive
literature review to compile updated medical and epidemi-
ological knowledge on the efficacy of medical procedures
to avoid amenable causes of death, considering “efficacy” as
the capacity to produce a desired result or effect under the
best conditions. Additionally, we complemented this strategy
by assessing the time trends of these causes of death in
two high-income countries, namely, Spain and the United
States. Although the quality of healthcare offered in these two
countries is very similar (i.e., both are based on advanced
medical knowledge and technology), they have very different
healthcare systems. By performing a comparative analysis
of the mortality rates in Spain and the United States, we
were able to assess the similarities and divergence in the
distribution. Second, we assessed the efficacy of these inter-
ventions by consulting a group of medical experts. Our final
intervention efficacy-based classification of amenable causes
of deathwas obtained froma consensus of both strategies (i.e.,
high or medium-high efficacy in Strategy 1; and In Strategy
2, >85% of experts assign the cause to the high efficacy
group).
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2.1. Strategy 1: Classification of Amenable Causes of Death
through Literature Review and Empirical Analysis. For each
of the 26 selected amenable causes of death, we gathered the
most up-to-date medical evidence and used it to determine
the degree of efficacy of the available interventions in avoid-
ing premature mortality. Specifically, we conducted a review
of clinical and epidemiological scientific literature, examining
various sources of health information including articles,
books, reports, and websites. We surveyed publications from
the years 2000 to 2016 by using search terms such as “efficacy”,
“intervention”, “health care”, “treatment”, “poor outcomes”,
and “mortality”, and by citing the specific cause of death.
This first phase of the literature review yielded 390 relevant
publications. We then filtered these publications by applying
a set of exclusion criteria. First, we excluded any publication
that was not eligible according to information in the title or
abstract (n = 212), or full-text (n = 88). Second, we excluded
any publication that did not contain relevant information for
classifying the causes of death based on intervention efficacy
(n = 43). In the end, we selected a total of 47 information
sources to help identify which of the 26 causes of death are
sentinel amenable causes.
Based on this literature review, we classified causes of
death as having (i) a high level of intervention efficacy (G1);
(ii) a low level of intervention efficacy (G2); or (iii) an
uncertain degree of intervention efficacy, with priority given
to high efficacy (G1/G2) or with priority given to low efficacy
(G2/G1). Next, we analysed and compared changes inmortal-
ity rates for these three different groups of amenable causes
of death. Using the World Health Organization (WHO)
standard population [25], we calculated direct standardized
mortality rates per 100,000 individuals in Spain and the
United States for 3-year periods spanning 1984 to 2004.
We obtained the mortality and population data for each
year, age group, and sex from the Spanish National Institute
of Statistics (INE) [26] for the Spanish analysis and from
the Centers for Disease Control (CDC) [27] and the US
Census Bureau [28] for the United States analysis. Changes in
mortality rates for each of the 26 causes of death andmortality
rates for the last period (2000-2004) are shown, respectively,
in Figures 1 and 2 and in Table 2.
2.2. Strategy 2: Classification of Amenable Causes of Death
according to the Opinions of Medical Experts. We conducted
in-depth interviews with 11 medical practitioners from a
university/tertiary hospital in Barcelona, Spain. These were
originally conducted in 2009 but also revisited in 2014.
We conducted the interviews (15 to 30 minutes) in the
hospital. The medical experts were mid-career doctors, 4
women and 7 men, specialized in internal medicine (n =
4), infectious diseases (n = 2), surgery and trauma (n =
2), anaesthesiology (n = 1), paediatrics (n = 1), and quality
of healthcare services (n = 1). After asking for an overall
assessment of the 26 amenable causes of death and the efficacy
levels of their associated medical interventions, we asked the
following specific question: “Which amenable causes of death
in the list could be avoided in a high percentage of cases
given currently available knowledge and technology used
in medical interventions in wealthy countries?” Using the
answers to the above question, we calculated the percentage
of experts that classified each amenable cause of death as
belonging to the group with the highest level of intervention
efficacy.
2.3. Combined Consensus Using Both Strategies. Finally,
according to the efficacy of their respective medical interven-
tions, we classified the causes of death as either high efficacy
or medium-low efficacy. In the high efficacy group, we
included only those causes of death that had been classified
as having a high intervention efficacy in both strategies.
3. Results
Table 3 summarizes the results obtained for the classification
of deaths amenable to medical intervention using the two
distinct strategies.
3.1. Strategy 1: Classification of Amenable Causes of
Death through Literature Review and Empirical Analysis
3.1.1. Literature Review. For all amenable causes of death
in the list, we found evidence concerning the efficacy of
their respective medical interventions [29, 30, 39]. In the
assessment of intervention efficacy, age groups are of special
concern [7, 9, 12]. While for most causes of death the
amenability of mortality is restricted to individuals aged 0-74
[7, 9, 12, 23], different age classifications have been discussed
for some conditions (described below).
After reviewing all available medical, scientific, and tech-
nological information, we classified amenable causes of death
into two groups.
The first group, labelled as G1 (“amenable causes with
medical interventions of high efficacy”), includes those causes
for which there is strong evidence of highly efficacious
medical interventions. This is clearly the case in many
surgical conditions such as appendicitis, abdominal hernias,
peptic ulcers, cholelithiasis/cholecystitis, and benign prostate
hyperplasia. Taking into account advances in surgical tech-
niques (e.g., laparoscopy and other noninvasive forms of
surgery), pharmacotherapy, and medical management of
complications, mortality resulting from these conditions
should be extremely low in most age groups.Thus, amenabil-
ity should only be age-restricted in cases when there are
also nonprevalent medical complications [9, 29, 30]. There is
also not much doubt regarding the high efficacy of medical
management for the most prevalent thyroid disorders and
asthma [12, 29, 30, 39, 40]. However, some authors recom-
mend restricting the amenability of asthma-related mortality
to middle age groups because of difficulties in distinguishing
its diagnosis as a cause of death among middle-aged adults
and the elderly [12, 23]. There is also a strong consensus
to not consider mortality due to infectious diseases such as
tetanus, diphtheria, whooping cough, poliomyelitis, measles,
and rubella, since there are effective vaccines for all of
these. Another condition that should be highly amenable
is pernicious anaemia (i.e., anaemia due to deficiencies in
iron, B12 vitamins, proteins, or other nutritional anaemia),
unless there is also a severe underlying disease such as cancer
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Figure 1: Evolution of amenable causes of death by sex, United States, 1984-2004. Colours in the figure: medium/low efficacy group (red) and
high efficacy group (green).
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Figure 2: Evolution of amenable causes of death by sex, Spain, 1984-2004. Colours in the figure: medium/low efficacy group (red) and high
efficacy group (green).
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Table 2: Age-standardized mortality rates per 100,000 population, by amenable cause of death and sex, United States and Spain, 2002-2004.
(a) Women
Cause of death Age group ICD-9 ICD-10 United States Spain
Ischemic heart disease 35-74 410-414 I20-I25 26,96 8,20
Breast cancer 0-74 174 C50 14,36 11,97
Cerebrovascular diseases 0-74 430-438 G45, F01.1, I60-69, 10,45 7,82
Perinatal mortality 760-779 P00-P96, A33 5,61 3,40
Hypertension 0-74 401-405 I10-I15 4,34 1,12





J02.0, J03.0), J10-J11, J12-J18
(except J18.2), J20-J22
3,42 1,45
Uterine cancer 15-74 182, 179 C54, C55 2,10 1,90
Cervical cancer 15-74 180 C53 1,81 1,41
Congenital cardiovascular anomalies 0-74 745-747 Q20-Q28, I51.0 1,27 1,33
Skin cancer (melanoma and
no-melanoma) 0-74 172,173 C43, C44, C46,0, C46,9 1,13 0,79
Diabetes mellitus 0-49 250 E10-E14 0,78 0,16
Chronic rheumatic cardiovascular disease 0-74 393-398 I05-I09 0,48 1,31
Maternal mortality All 630-676 O00-O99, A34 0,40 0,08
Asthma 5-49 493 J45-J46 0,32 0,10
Peptic ulcers 0-74 531-534 K25-K28 0,31 0,14
Hodgkin’s disease 0-74 201 C81 0,25 0,21
Cholelithiasis/cholecystitis 0-74 574-575 K80-K82 0,23 0,25
Leukemia 0-14 204-208 C91-C95 0,18 2,13
Abdominal hernia 0-74 550-553 K40-K46 0,16 0,14
Thyroid diseases 0-74 240-246 E00-E07 0,15 0,13
Pernicious anemia 0-74 280-281 D50-D53 0,11 0,02
Tuberculosis 0-74 010-018 137 A15-A19, B90 0,08 0,17






A35, A36, A37, A49.2, A80,
B05, B06, B15, B16, B17,0,
B18,0-B18,1, B26
0,01 0,07
Data sorted descendent by age-standardized mortality rates in the United States.
(b) Men
Cause of death Age group ICD-9 ICD-10 United States Spain
Ischemic heart disease 35-74 410-414 I20-I25 65,79 33,12
Cerebrovascular diseases 0-74 430-438 G45, F01.1, I60-69, 13,08 14,64
Hypertension 0-74 401-405 I10-I15 7,16 1,73
Perinatal mortality 760-779 P00-P96, A33 7,06 4,32





J02.0, J03.0), J10-J11, J12-J18
(except J18.2), J20-J22
5,05 3,67
Skin cancer (melanoma and
no-melanoma) 0-74 172,173 C43, C44, C46,0, C46,9 2,57 1,33
Congenital cardiovascular anomalies 0-74 745-747 Q20-Q28, I51.0 1,57 1,73
Diabetes mellitus 0-49 250 E10-E14 1,18 0,37
Peptic ulcers 0-74 531-534 K25-K28 0,52 0,48
Hodgkin’s disease 0-74 201 C81 0,36 0,39
Asthma 5-49 493 J45-J46 0,34 0,16
Chronic rheumatic cardiovascular disease 0-74 393-398 I05-I09 0,32 0,81
Cholelithiasis/cholecystitis 0-74 574-575 K80-K82 0,30 0,42
Pernicious anaemia 0-74 280-281 D50-D53 0,29 0,03
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Table 2: Continued.
Cause of death Age group ICD-9 ICD-10 United States Spain
Testicular cancer 0-74 186 C62 0,23 0,14
Leukemia 0-14 204-208 C91-C95 0,22 3,48
Tuberculosis 0-74 010-018 137 A15-A19, B90 0,18 0,58
Abdominal hernia 0-74 550-553 K40-K46 0,17 0,14
Appendix diseases 0-74 540-543 K35-K38 0,10 0,07
Thyroid diseases 0-74 240-246 E00-E07 0,08 0,03






A35, A36, A37, A49.2, A80,
B05, B06, B15, B16, B17,0,
B18,0-B18,1, B26
0,02 0,19
Data sorted descendent by age-standardized mortality rates in the United States.
[29, 30].Maternal mortality, which includes numerous causes
of death, should also be largely avoidable if the mother is
provided with adequate obstetric and prenatal care [31–33].
In fact, mortality due to this condition is considered rare in
high-income countries and, togetherwith perinatalmortality,
is one of the most relevant indicators of health and quality
in healthcare systems. The efficacy of medical interventions
in the management of perinatal deaths is, however, more
controversial [34–36]. While the two conditions involve a
complex set of medical interventions that aim to avoid death,
considering the overall levels of efficacy achieved in high-
income countries for conditions related to both maternal and
perinatal mortality should be included in the high efficacy
group.
The second group contains the remaining amenable causes
of death which, according to current knowledge and tech-
nology, have lower levels of intervention efficacy. We call
this group G2: “amenable causes with medical interventions
of medium-low efficacy”. In this group, we included causes
of death such as cardiovascular diseases (ischemic heart
disease, IHD) and cerebrovascular diseases, which are highly
prevalent in the population and are generally considered to
be only partly amenable to current medical interventions
(i.e., pharmacotherapy, lifestyle modifications and adherence
to treatment) [7]. Nonetheless, the efficacy of the treatment
andmanagement of these causes have improved considerably
in recent years [7, 9, 29, 30, 67]. These diseases require
urgent treatment and highly specialized health care, such that
having good accessibility to IHD and stroke units is highly
important. They should also be tackled from a public health
perspective (i.e., primary prevention) to help reduce risk
factors. We also included diabetes, pneumonia, and hyper-
tension in this group [9, 29, 30, 53, 56–59]. While mortality
due to diabetes is considered amenable until middle age
(about 50 years), patients with type 1 diabetes can also suffer
major complications at a younger age [53]. Hypertension,
pneumonia, acute respiratory infections, and influenza are
conditions with a high level of nonamenable mortality in the
presence of comorbidity [9, 29, 30, 56, 57], especially in the
elderly or in people with depressed immune systems.
All cancers in the list of amenable causes were also
included in this second group. Although patients with
Hodgkin’s disease and testicular cancer now have increased
survival rates (>5 years) [62, 64], there are many factors such
as the nature of the disease, early detection, stage of the
cancer, toxicity of treatments, and metastatic processes that
can critically influence their outcome and complete cure rate
[60–64, 66, 68]. These factors also affect other cancers such
as breast and cervical cancer despite significantly increased
knowledge regarding their etiology, treatment, and early
detection through screening programs [61, 68]. Prognosis and
medical achievements are even less favourable in relation to
other forms of cancer, such as uterine or skin cancer [29, 30,
62].
Based on our literature review, we were unsure how to
best classify conditions such as cardiovascular congenital
anomalies and chronic rheumatic heart disease. Although
there have been many advances in surgical and medical
interventions aimed at avoiding premature deaths due to
these conditions, the prognosis or the degree of efficacy of
the interventions depends on the type of anomaly [9, 29, 30,
51, 52]. In the case of chronic rheumatic heart disease, we
must consider a change in its etiology. While improvements
in pharmacotherapy and antibiotics reduce rheumatic fever-
related cases, other forms of heart-valve disease are emerging
as a consequence of increased life expectancy [51]. Thus,
premature deaths caused by this disease should only be con-
sidered highly amenable to currently available interventions
when dealing with younger age groups.
Finally, we also included tuberculosis in this second
group, even though its etiology, incidence, and prevalence
make its classification more controversial. Tuberculosis is an
old infectious disease that still constitutes an important public
health problem worldwide [44, 45]. After the identification
of this bacillus and the subsequent development of appropri-
ate pharmacotherapy, this condition was considered highly
treatable by health services. In recent decades, however, some
well-known factors, such as having a depressed immune
system and, in particular, the presence of AIDS, have been
found to result in a poor prognosis [46]. Moreover, in the last

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Evolution of age-adjusted amenable mortality rate by efficacy group and sex. United States and Spain, 1984-2004. High efficacy:
amenable causes with medical interventions of high efficacy (G1); low efficacy: amenable causes with medical interventions of low efficacy
(G2); and medium efficacy: uncertain level of efficacy but priority given to the first (G1/G2 or G2/G1). Three-way categories were based
exclusively on the literature review.
few years, additional complications have emerged, including
the spread of multidrug-resistant strains mainly due to poor
patient compliance with treatment [47–50]. These emerging
problems diminish the level of efficacy of current medical
treatments and urgently demand further advances in the
knowledge and management of this disease.
3.1.2. Empirical Analysis. In Figure 3, we show the evolution
of age-adjusted mortality rates from 1984 to 2004 for three
groups of amenable causes of death, for both women and
men in Spain and the United States (see Figures 1 and 2 for
more detailed information about the time trends of each of
the 26 amenable causes of death). Classification of the causes
of death into the three groups was based on the efficacy levels
of their respective treatments as determined by the literature
review (Table 3, Strategy 1): high (G1 or G1/G2), medium
efficacy (G2/G1), and low efficacy (G2)).
While the time trend of mortality rates is very similar
in both countries, we observe higher mortality rates in the
United States than in Spain for the low efficacy group in
both sexes and for the medium efficacy group in men. In
particular, we also observe that the most pronounced decline
in age-adjusted mortality rates is for the low efficacy group.
On the other hand, those amenable causes of death belong-
ing to the high efficacy group present the lowest rates of
mortality.
3.2. Strategy 2: Classification of Amenable Causes of Death
according to the Opinions of Medical Experts. A very high
percentage of the medical experts (more than 85%) classified
maternal and perinatal causes of mortality, surgical condi-
tions, pernicious anaemia, and thyroid and immunizable dis-
eases into the high efficacy group. In contrast, only a medium
(50-85%) or low (<50%) percentage of experts classified
cardiovascular diseases (including congenital cardiovascular
anomalies) and most cancers into the high efficacy group.
Finally, there was some disagreement regarding the classifica-
tion of chronic rheumatic heart disease, pneumonia, hyper-
tension, and diabetes, as only a medium level of agreement
was reached.
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3.3. Combined Consensus Using Both Strategies. For most
causes of death, we obtained similar results between strate-
gies. Those amenable causes of death for which only weak
evidence was found to classify them into the high efficacy
group were classified into the medium-low efficacy group
(hypertension, diabetes mellitus, chronic rheumatic heart
disease, and congenital cardiovascular diseases).
Based on the literature review alone, it was not clear how
to classify perinatal mortality. Consequently, we decided to
follow the criteria of the medical experts. A similar situation
occurred for certain cancers (cervical cancer, testicular can-
cer, and Hodgkin’s disease). In these cases, however, given
the low degree of agreement reached by the experts, we
placed them into the medium-low efficacy group. Finally, we
also decided to keep tuberculosis in the medium-low efficacy
group because of the aforementioned limitations uncovered
in the literature review.
4. Discussion
In this study, we propose a new way to classify causes of
avoidable premature mortality which are amenable to med-
ical care. Using available scientific and medical knowledge,
we show that it is possible to differentiate between causes of
death based on the level of efficacy of their respective medical
interventions. To our knowledge, this is the first proposal that
aims to classifying amenable causes of death in accordance
with the efficacy of medical interventions.
Using this approach, we have obtained a highly specific
and homogeneous group of amenable causes of death for
which medical interventions are highly efficacious. These
causes of death, hereafter sentinel amenable mortality, are
useful for assessing the quality of healthcare services as a
sentinel indicator.
For the final classification, we decided to classify causes of
death into one of two categories: high or medium-low level of
efficacy. Importantly, this selection was based on conservative
criteria, so that if we were unsure about the level of efficacy
of a medical intervention, the respective cause of death was
classified into themedium-low category.
For the purpose of making this two-group classification
scheme, we combined several different information-seeking
strategies (literature review, empirical analysis, and expert
assessment) instead of performing just a systematic review.
There were two main reasons behind this multistrategy
approach. First, it is difficult to categorize evidence on the
efficacy of medical interventions since the available evidence
is both voluminous and highly variable for each cause of
death. Second, we wanted to reach a deeper understanding by
identifying information that is important for distinguishing
between the efficacy levels of medical interventions.
Empirical analysis, showing time trends in age-adjusted
mortality rates in Spain and the United States, was useful
not only for assessing the similarities and divergence in the
distribution of each amenable cause of death, but also for
performing the preliminary categorization into the three
different efficacy groups. Despite large differences between
the national health systems of Spain and theUnited States, the
two countries are similar in terms of efficacy (i.e., healthcare
performance), in that they both employ advanced medical
knowledge and technologies; however, they are quite different
in the effectiveness of the interventions, for example, in terms
of accessibility.
The overall consistency in the distribution and evolution
of mortality rates in both Spain and the United States
reinforces our hypothesis that the causes of amenable mor-
tality are heterogeneous. This in turn justifies our use of
intervention efficacy as a mode of classification. Indeed, the
amenable causes of death that we classified into the highest
efficacy group generally showed the lowest mortality rates in
both countries (data shown in Figures 1 and 2), albeit with a
few exceptions.
In the high efficacy group, perinatal mortality in both
sexes and peptic ulcers in men showed higher mortality rates
than the other amenable causes in this group. One possible
reason for the divergence in perinatal mortality could be the
presence of biases in the mortality records. Some studies have
shown that international differences in published perinatal
mortality rates may partly reflect differences in the criteria
used to record and publish them [37, 38]. However, since we
observed similar results in both countries, the high mortality
due to this condition is not likely to be a categorization issue.
In fact, we found that a high percentage of medical experts
agreed on classifying perinatal mortality into the highest effi-
cacy group.Thus, despite the availability of highly efficacious
interventions for perinatal mortality, the high mortality rates
in high-income countries could be explained by a lack of
effectiveness of healthcare services [34]. Moreover, in high-
income countries, high mortality rates are more strongly
associated with a lack of access to healthcare than with the
degree of efficacy of the medical interventions themselves
[35, 36]. With respect to peptic ulcers, we also observed
high mortality rates during the period studied. In this case,
we should not only consider potential deficiencies in the
effectiveness of medical interventions, but also the presence
of severe complications that could limit the amenability of
this cause of death [41–43].
Within the medium-low efficacy group, we observed a
generalized decline of amenable mortality, probably due
to achievements in the effectiveness of medical interven-
tions but also to social determinants of health. We found
exceptions in both countries. First, in the case of Hodgkin’s
disease and testicular cancer, mortality rates were very low
in comparison to the rest of the amenable causes. Clearly,
noticeable achievements in the management of these cancers
have been made in recent years, and ultimately these have led
to a considerable increase in the cure rate among patients.
Therefore, these two cancers could actually be considered to
belong to the highest efficacy group. In our list, however, we
decided not to include these causes in the high efficacy group
because their treatments have limited efficacy at later stages
of the disease and these diseases are often characterized by
metastasis [65]. Additionally, studies showing better results
in the prognosis of testicular cancer andHodgkin’s disease are
mainly based on survival indicators. In particular, it is worth
noting that Hodgkin’s disease survival is only better in the
early stages [60, 64]. Second, we also observed considerably
low mortality for diabetes in both countries, especially in
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Spain. For this condition, we only selected cases in which the
patient was aged under 50. Although the efficacy of medical
interventions applied to this age groupmight be higher, type 1
diabetesmay still present complications at earlier ages.On the
other hand, we must consider limitations in the registration
of mortality data for this condition [54, 55], which may
partly explain lower mortality rates. In the end, we decided to
assign this condition to the lower efficacy group because it is
an important risk factor for major complications, especially
in the presence of comorbidity. Finally, for tuberculosis,
we also observed lower mortality rates and specifically a
significant decrease in the rates over the study period for both
countries, particularly among women. For this condition,
high levels of effectiveness have been achieved in high-
income countries. Nevertheless, the burden of other related
diseases such asAIDS, the extensive emergence ofmultidrug-
resistant strains, and the difficulty in enforcing treatment
compliance make it necessary to develop new treatments to
ensure both greater efficacy and effectiveness in the presence
of medical complications. [46–50]
We mention some potential limitations of our study. We
used a standardized list of amenable causes of death created
by Spanish researchers. Although this list is not very different
compared to other lists found in the literature, it does exclude
certain causes of death, such as colon cancer, nephritis and
nephrosis, and epilepsy that appear in other international
lists [7, 8] and in particular, in recent studies conducted in
the United States [69]. Nonetheless, the fact that there is a
discussion about whether these causes of death should be
included in the list is another reason to categorize them into
the lowest efficacy group.
For most amenable causes of death, we considered the
standard age group to be those patients aged between 0 and 74
years. In recent years, improvements in disease management
have been introduced both for the youngest groups and
among the elderly. However, taking into account the burden
of comorbidity and difficulties in managing some diseases
among the elderly, we should discuss whether the efficacy of
some medical interventions should only be considered high
for those under 65. This is the case, for instance, in chronic
rheumatic heart disease and the emerging forms of less-
amenable valve diseases at older ages [52]. For a few causes
of death such as peptic ulcers and tuberculosis, we observed
some differences between the sexes. These differences might
be due to the etiology of the diseases or may even be related
to limitations in efficacy [29, 30]. Thus, in the future it may
be worthwhile to classify amenable causes of death according
to sex and not only in relation to the efficacy of medical
interventions [70].
With respect to the empirical analysis, it is important to
consider the quality and variability of the certification and
coding of the underlying causes of death, or in other words,
changes to the classification of ICD codes and interpretation
of the data. With regard to the former issue, the overall
quality of mortality data has been recognized as reasonable
for both countries [71, 72]. In terms of variability, we should
consider that differences in mortality rates and trends could
be due to the varying effectiveness of medical interventions
and to socioeconomic or environmental determinants. For
rare amenable causes of death, case-fatality rates, rather than
population-based mortality rates, might help to clarify the
efficacy of relevant interventions. Nevertheless, incidence
data are not easily accessible, and analysing a specific study
for each amenable cause of death falls far from the scope of
this study. It could, however, be the next step in future studies
examining the quality of healthcare after an increment in the
sentinel amenable mortality indicator is detected.
Finally, consulting a group of medical experts to help
classify causes of death has the intrinsic limitation of bias in
selecting its members. However, the group we chose came
from a public university hospital in Spain and was composed
of well-informed medical experts who were specialized in
interventions related to the considered causes of death.
In this study, we show that it is possible to separate out
those causes of death that are highly amenable in all countries.
As we mentioned above, such causes could be considered
sentinel health events and could help in assessing the quality of
health services worldwide. As we found lower mortality rates
in both countries for those amenable causes of death in the
high efficacy group, high mortality rates or any such events
due to these causes aremore clearly related to the effectiveness
of health services.
Amenable causes of death that were classified into the
medium-low efficacy group are still a great challenge for sci-
ence, technology, andmedicine. With respect to these causes,
the development of more effective public healthcare systems
and interventions that take into account environmental,
social, and economic factors will prove critical in the future.
Divergence between the theoretical and empirical results
obtained in our study may suggest some limitations with
respect to our proposed classification method and/or issues
related to the effectiveness of healthcare services. To our
knowledge, this is the first ever proposal to classify amenable
causes of death according to the efficacy level of their
respective interventions. To validate our proposal, similar
initiatives in different contexts or using different approaches
are needed. We should also consider, however, the potential
inequalities or difficulties of healthcare services in terms
of patients being able to access highly efficacious medical
interventions. Besides being affected by the characteristics of
public health and healthcare systems, this accessibility issue
is also influenced by other medical, environmental, political,
and economic factors.
In conclusion, the separation of sentinel events of
amenable causes of death, or those whose medical inter-
ventions have high efficacy, might be useful for measuring
differences and anomalies in healthcare performance. This
distinction could therefore be a good indicator for detecting
inequalities among populations served by different health
services both within and between countries. This novel way
of classifying amenable mortality can also help to accurately
pinpoint the degree to which different causes of death can
be avoided. Furthermore, it is also useful in improving the
knowledge required to conduct studies on the effectiveness
of healthcare services, studies which ultimately aim to reduce
mortality induced by these causes. Finally, this method
should be continuously discussed and updated in accordance
with new medical and technological advances.
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[42] J. T. Mäkelä, H. Kiviniemi, P. Ohtonen, and S. O. Laitinen,
“Factors that predict morbidity and mortality in patients with
perforated peptic ulcers,” European Journal of Surgery, vol. 168,
no. 8-9, pp. 446–451, 2002.
[43] R. Riley, “Peptic ulcers: mortality and hospitalization,” Health
Reports, vol. 3, no. 3, pp. 245–257, 1991.
[44] A. P. Ralph, N. M. Anstey, and P. M. Kelly, “Tuberculosis into
the 2010s: Is the glass half full?” Clinical Infectious Diseases, vol.
49, no. 4, pp. 574–583, 2009.
[45] T. Vasankari, P.Holmström, J. Ollgren, K. Liippo,M. Kokki, and
P. Ruutu, “Risk factors for poor tuberculosis treatment outcome
in Finland: a cohort study,”BMCPublic Health, vol. 7, article 291,
2007.
[46] D. J. Pepper, K. Rebe, C.Morroni, R. J.Wilkinson, andG. Mein-
tjes, “Clinical deterioration during antitubercular treatment at
a district hospital in South Africa: The importance of drug
resistance and AIDS defining illnesses,” PLoS ONE, vol. 4, no.
2, 2009.
[47] L. P. Ormerod, “Multidrug-resistant tuberculosis (MDR-TB):
Epidemiology, prevention and treatment,” British Medical Bul-
letin, vol. 73-74, pp. 17–24, 2005.
[48] W. A. Geerligs, R. Van Altena, W. C. M. De Lange, D.
Van Soolingen, and T. S. Van Der Werf, “Multidrug-resistant
tuberculosis: long-term treatment outcome in theNetherlands,”
International Journal of Tuberculosis and Lung Disease, vol. 4,
no. 8, pp. 758–764, 2000.
[49] E. D. Chan and M. D. Iseman, “Multidrug-resistant and exten-
sively drug-resistant tuberculosis: a review,”Current Opinion in
Infectious Diseases, vol. 21, no. 6, pp. 587–595, 2008.
[50] G. B. Migliori, A. Matteelli, D. Cirillo, and M. Pai, “Diagnosis
of Multidrug-Resistant Tuberculosis and Extensively Drug-
Resistant Tuberculosis: Current Standards and Challenges,”
Canadian Journal of Infectious Diseases &MedicalMicrobiology,
vol. 19, no. 2, Article ID 857901, pp. 169–172, 2008.
[51] fundaciondelcorazon.com, Valvulopat́ıas. Madrid: La Aso-
ciación.
[52] J. Azpitarte, A. M. Alonso, F. Garcia Gallego, JM. González
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